Breaking News Instant updates and real-time market news.

SPWH

Sportsman's Warehouse

$4.73

-0.12 (-2.47%)

, ADSK

Autodesk

$95.83

1.86 (1.98%)

17:31
05/18/17
05/18
17:31
05/18/17
17:31

On The Fly: After Hours Movers

UP AFTER EARNINGS: Sportsman's Warehouse (SPWH), up 13.1%... Autodesk (ADSK), up 10.7%... Safe Bulkers (SB), up 8.3%... McKesson (MCK), up 8.2%... Gap (GPS), up 3.7%... Ross Stores (ROST), up 3.2%... Applied Materials (AMAT), up 2.7%. ALSO HIGHER: Egalet (EGLT), up 1% after it said that analysis of its ARYMO ER results showed that introduction of ARYMO ER may be associated with fewer abuse-related emergency department visits, outpatient visits, hospitalizations, substance abuse treatments, injection related diseases and deaths... Nvidia (NVDA), up 0.7% after the stock was initiated with an Outperform rating at Bernstein. LOWER: XBiotech (XBIT), down 15% after it said that it received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its Marketing Authorization Application for its lead product candidate in Europe... Halozyme (HALO), down 7.8% after it filed to sell $100M in common stock... Goldman Sachs BDC (GSBD), down 3% after it filed to sell 3.25M shares of common stock... RSP Permian (RSPP), down 2.9% after it filed to sell 15M shares of common stock.

SPWH

Sportsman's Warehouse

$4.73

-0.12 (-2.47%)

ADSK

Autodesk

$95.83

1.86 (1.98%)

SB

Safe Bulkers

$2.06

-0.04 (-1.90%)

MCK

McKesson

$141.44

-0.6 (-0.42%)

GPS

Gap

$23.19

-0.36 (-1.53%)

ROST

Ross Stores

$61.07

-0.45 (-0.73%)

AMAT

Applied Materials

$43.91

1.15 (2.69%)

EGLT

Egalet

NVDA

Nvidia

$133.07

5.35 (4.19%)

XBIT

XBiotech

$8.82

-0.13 (-1.45%)

HALO

Halozyme

$14.16

0.4 (2.91%)

GSBD

Goldman Sachs BDC

$23.08

-0.25 (-1.07%)

RSPP

RSP Permian

$40.69

0.2 (0.49%)

  • 18

    May

  • 18

    May

  • 18

    May

  • 18

    May

  • 18

    May

  • 18

    May

  • 18

    May

  • 19

    May

  • 19

    May

  • 22

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 26

    May

  • 30

    May

  • 31

    May

  • 31

    May

  • 01

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 09

    Jun

  • 14

    Jun

  • 20

    Jun

  • 19

    May

  • 19

    May

  • 19

    May

SPWH Sportsman's Warehouse
$4.73

-0.12 (-2.47%)

03/26/17
GSCO
03/26/17
DOWNGRADE
Target $6.5
GSCO
Neutral
Sportsman's Warehouse downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Stephen Tanal downgraded Sportsman's Warehouse to Neutral citing a lack of positive catalysts given the retailer's recent same-store-sales declines. The analyst cut his price target for the shares to $6.50 from $8.50. The stock is down over 50% year-to-date and closed Friday down 39c to $4.64. Tanal sees "some likelihood" that credit and/or liquidity constraints will force Sportsman's to slow its pace of expansion. He sees the stock struggling to move higher until firearm comparisons ease in the fall.
03/24/17
BARD
03/24/17
NO CHANGE
Target $8
BARD
Outperform
Sportsman's Warehouse valuation provides long-term opportunity, says Baird
Baird analyst Peter Benedict noted Sportsman's Warehouse Q4 results were soft and 2017 is expected to be a challenging year but he believes the longer-term risk/reward looks compelling. He cited the company's above average long-term underlying earnings growth prospects. Benedict maintained his Outperform rating and lowered his price target to $8 from $12 on Sportsman's Warehouse shares.
03/24/17
PIPR
03/24/17
DOWNGRADE
Target $4
PIPR
Neutral
Sportsman's Warehouse downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Peter Keith downgraded Sportsman's Warehouse to Neutral citing the potential for covenant violations by Q4 or early 2018. Renegotiations of the covenant terms would likely cause a large increase in interest rates, the analyst contends. He cut his price target for the shares to $4 from $10 following Sportsman's Q4 results.
03/15/17
DADA
03/15/17
NO CHANGE
DADA
Sportsman's Warehouse price target lowered to $7 from $11 at DA Davidson
DA Davidson analyst Andrew Burns says that comments from firearms companies suggest that demand for firearms is "softening," but he says that data indicates that the sector is in the midst of " a normal post-surge correction," rather than a tremendous slump. He thinks that Sportsman's Warehouse's balance sheet is "on solid footing entering the downturn," but lowered his estimates for the company slightly to reflect weakening demand. However, he keeps a Buy rating on the shares.
ADSK Autodesk
$95.83

1.86 (1.98%)

05/09/17
WEDB
05/09/17
UPGRADE
WEDB
Outperform
Autodesk upgraded to Outperform from Neutral at Wedbush
05/01/17
MSCO
05/01/17
UPGRADE
Target $115
MSCO
Overweight
Autodesk upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Keith Weiss upgraded Autodesk to Overweight with a $115 price target citing increased visibility towards a subscription model, yielding more free-cash-flow from a "sticky" customer base. Weiss sees increased free cash flow yield from several initiatives to better monetize the 20M+ installed base including higher pricing for maintenance customers, pushing active users not paying maintenance into a subscription, new cloud based offerings, and more efficiently selling into the base.
05/09/17
WEDB
05/09/17
UPGRADE
WEDB
Outperform
Autodesk upgraded on positive checks, developments at Wedbush
As noted earlier, Wedbush upgraded Autodesk to Outperform from Neutral . Analyst Steve Koenig says his checks indicate that the sales of the company's collections business are rising, while customers appears to be interested in its M2S program. Additionally, its "end market conditions have stabilized, and its channel partners appear to be "embracing" its subscriptions, Koenig reported. As a result, the analyst is more confident that the company's results will become more predictable and that it can meet its long-term targets. He raised his fiscal 2020 free cash flow estimate by about 30% and increased his price target to $120 from $78.
05/16/17
COWN
05/16/17
NO CHANGE
Target $105
COWN
Outperform
Autodesk price target raised to $105 from $95 at Cowen
Cowen analyst Gregg Moskowitz raised his price target on Autodesk to $105 from $95 ahead of Q1 results this Thursday. The analyst expects to see upside to consensus estimates for net subscriptions additions and he continues to see more longer term upside as the company executes its business model transition. Moskowitz reiterated his Outperform rating on Autodesk shares.
SB Safe Bulkers
$2.06

-0.04 (-1.90%)

01/27/17
DNBM
01/27/17
UPGRADE
DNBM
Buy
Safe Bulkers upgraded to Buy from Hold at DNB Markets
02/24/17
EVER
02/24/17
UPGRADE
EVER
Hold
Safe Bulkers upgraded to Hold from Sell at Evercore ISI
Evercore ISI analyst Jonathan Chappell upgraded Safe Bulkers to Hold with a $1.50 price target saying the company has vastly improved its capital structure and liquidity profile .
03/28/17
MSCO
03/28/17
UPGRADE
MSCO
Overweight
Safe Bulkers upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Fortis Giannakoulis upgraded Safe Bulkers to Overweight and raised its price target to $3 from $1.30. The analyst sees potential upside across the entire dry bulk shipping sector as long as steel prices remain high and fleet supply growth declines. As a result, Giannakoulis raised estimates and price targets across the dry bulk shipping sector.
03/28/17
03/28/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Commercial Metals (CMC) upgraded to Outperform at Credit Suisse with analyst Curt Woodworth saying the company should see "significant" EBITDA growth over the fiscal 2017-2019 time frame, driven by solid volume growth and metal spread expansion. The analyst also raised his price target on the shares to $24 from $19. 2. Columbia Property (CXP) upgraded to Outperform from In Line at Evercore ISI with analyst Sheila McGrath citing the recent pullback in shares. 3. Sasol (SSL) upgraded to Buy from Hold at HSBC with analyst Sriharsha Pappu saying he expects a free cash flow "pivot" with the company nearing the end of its cracker capital expenditure cycle and sees limited downside from current share levels. 4. Premier (PINC) upgraded to Buy from Underperform at BofA/Merrill analyst Steven Valiquette upgrading Premier two notches, raising its price target to $37 from $32, and saying Congress's inability to repeal the Affordable Care Act sets the stage for better results. 5. Star Bulk Carriers (SBLK) was upgraded to Overweight from Underweight at Morgan Stanley, while Safe Bulkers (SB), Golden Ocean (GOGL), and Genco Shipping (GNK) were upgraded to Equal Weight from Underweight. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MCK McKesson
$141.44

-0.6 (-0.42%)

05/17/17
JEFF
05/17/17
INITIATION
Target $153
JEFF
Hold
McKesson initiated with a Hold at Jefferies
Jefferies analyst Brian Tanquilut started McKesson with a Hold rating and $153 price target. The analyst expects accelerating generic drug price deflation and moderating brand drug inflation will continue to pressure the company's growth.
05/11/17
WELS
05/11/17
NO CHANGE
WELS
Market Perform
Teva faces 'underappreciated risk' from major generic RFPs, says Wells Fargo
Wells Fargo analyst David Maris noted that Teva's generic drug price erosion came in at 7% in Q1, adding that Teva's management, which previously indicated that they expected price erosion in the U.S. to be 5%, "did not explain well" how the factors that negatively impacted prices were not fully anticipated. Also, there are currently two major generic Request for Proposals out for bid - one from Express Scripts (ESRX), Albertson's and Kroger (KR) and one from Walmart (WMT) and McKesson (MCK) - and the potential price reset from these is an "underappreciated risk" facing Teva, added Maris, who keeps a Market Perform rating on the stock.
04/21/17
LEER
04/21/17
NO CHANGE
Target $140
LEER
Market Perform
McKesson price target lowered to $140 from $155 at Leerink
Leerink analyst David Larsen lowered his price target for McKesson to $140 from $155 ahead of Q4 results and 2018 guide as the analyst is incrementally more cautious on the stock following the company's pre-announcement. Larsen reiterates a Market Perform rating on the shares.
04/18/17
LEER
04/18/17
NO CHANGE
LEER
Market Perform
Cardinal Health struggles may be benefitting AmerisourceBergen, says Leerink
Leerink analyst David Larsen noted that Cardinal Health (CAH) pointed to generic pricing and sell-side pressure and incremental investments as primary reasons for its FY18 and FY19 adjusted EPS forecasts missing expectations, but he believes there may be other challenges the business is facing too. Cardinal's loss of Prime Therapeutics and Walgreens' (WBA) recent wins from CVS Health (CVS) are other factors that may have hurt Cardinal, said Larsen, who added that both of those will benefit AmerisourceBergen (ABC). The analyst, who also said he is incrementally more cautious on McKesson (MCK) and Owens & Minor (OMI) after Cardinal's call, has an Outperform rating on AmerisourceBergen and Market Perform ratings on Cardinal Health, McKesson and O&M.
GPS Gap
$23.19

-0.36 (-1.53%)

04/20/17
04/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Stifel with analyst Mark Astrachan saying he views valuation as attractive and expects multiple expansion from accelerating U.S. comparable store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations. 2. Goldman Sachs (GS) upgraded to Overweight from Neutral at Atlantic Equities with analyst Christopher Wheeler telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures. 3. Lear (LEA) upgraded to Outperform from Neutral at Baird with analyst David Leiker citing its recent underperformance despite improving fundamentals and a strong global auto backdrop. Leiker raised his price target to $161 from $160 on Lear shares. 4. Discovery (DISCA) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying he sees little chance of material downward revisions to consensus earnings estimates. The analyst views the risk/reward as more balanced at current levels and upped his price target for the shares to $30 from $27. 5. Gap (GPS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/17
GUGG
03/08/17
INITIATION
GUGG
Neutral
Gap initiated with a Neutral at Guggenheim
04/20/17
JPMS
04/20/17
UPGRADE
Target $24
JPMS
Neutral
Gap upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Matthew Boss upgraded The Gap to Neutral citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21.
02/07/17
JEFF
02/07/17
NO CHANGE
Target $36
JEFF
Buy
Jefferies calls on Gap to consider alternatives for Banana
While the Gap brand last night reported its second consecutive month of positive comparable sales, and Old Navy remained positive, Banana Republic continued to struggle with comp sales down 4%, Jefferies analyst Randal Konik tells investors in a research note. Management needs to take action, the analyst argues. He believes management should consider strategic alternatives for Banana including a potential sale, massively reducing the store footprint, or shutting down the brand. Konik has a Buy rating on Gap with a $36 price target.
ROST Ross Stores
$61.07

-0.45 (-0.73%)

03/01/17
03/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Underperform from Market Perform at Bernstein with analyst Stacy Rasgon saying the beginnings of a multi-year structural downturn are beginning to show. The analyst believes Intel's datacenter growth is "beginning to crack" amid compressing margins and an increasingly competitive environment. "The world seems to be moving against Intel's strengths," Rasgon writes. 2. Palo Alto Networks (PANW) downgraded to Equal Weight from Overweight at Morgan Stanley, to Market Perform at William Blair, to Neutral from Outperform at Baird, and to Neutral from Overweight at JPMorgan. 3. Waste Management (WM) downgraded to Equal Weight from Overweight at Barclays with analyst Jon Windham citing high valuations in the municipal solid waste space following the recent rally. Most of the upside from potential tax reform is already reflected in Waste Management shares, Windham tells investors in a research note. He raised his price target for the name to $73 from $70. 4. Signet Jewelers (SIG) downgraded to Market Perform from Outperform at Telsey Advisory. 5. Ross Stores (ROST) downgraded to Neutral from Buy at Citi with analyst Paul Lejuez saying the risk/reward is more balanced with the shares close to his unchanged price target to $72. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/10/17
SUSQ
02/10/17
INITIATION
Target $80
SUSQ
Positive
Ross Stores initiated with a Positive at Susquehanna
Target $80.
12/19/16
12/19/16
NO CHANGE

Wells Fargo identifies retailers best positioned for Trump policies
Wells Fargo identifies Burlington Stores (BURL), TJX (TJX), Ross Stores (ROST), Tiffany (TIF), Signet Jewelers (SIG), Ulta Beauty (ULTA) and Foot Locker (FL) as the retailers that are best positioned to benefit from upcoming federal policy changes.
03/01/17
SBSH
03/01/17
DOWNGRADE
Target $72
SBSH
Neutral
Ross Stores downgraded to Neutral from Buy at Citi
Citi analyst Paul Lejuez downgraded Ross Stores to Neutral saying the risk/reward is more balanced with the shares close to his unchanged price target to $72.
AMAT Applied Materials
$43.91

1.15 (2.69%)

05/16/17
BOFA
05/16/17
NO CHANGE
Target $54
BOFA
Buy
Applied Materials still has upside, price target up to $54 at BofA/Merrill
BofA/Merrill analyst Krish Sankar continues to have a bullish views on Buy rated Applied Materials despite the strong performance year-to-date. The analyst said semicap fundamentals remain strong, with slower capex discounted, China investments starting next year, and the upcoming 7nm logic/foundry investment cycle driven by mobile and auto's. Sankar also expects OLED strength driven by new products and more mobile makers adoption. The analyst expects another beat and raise quarter and increased estimates and his price target to $54 from $45.
05/16/17
UBSW
05/16/17
NO CHANGE
Target $51
UBSW
Buy
Applied Materials price target raised to $51 from $44 at UBS
UBS analyst Stephen Chin raised his price target on Applied Materials to $51 from $44 to reflect more confidence in China's potential to purchase semi capital equipment following the building of memory fabs that are well into foundational stages of construction. Chin reiterated his Buy rating on Applied Materials shares.
05/15/17
SBSH
05/15/17
NO CHANGE
Target $200
SBSH
Buy
Citi ups Lam target to $200, Applied Materials target to $50
Citi analyst Atif Malik raised his price target for Lam Research (LRCX) to $200 from $161, for Applied Materials (AMAT) to $50 from $43 and for KLA-Tencor (KLAC) to $110 from $102. The first two names are Buy rated while the latter is Hold rated. To reflect higher 3D NAND investment expectations, Malik upped his 2018 wafer fab equipment spending target to $43B from $40B. Lam and AMAT are best positioned to benefit from sustained 3D NAND investments, Malik tells investors in a research note.
05/16/17
DADA
05/16/17
NO CHANGE
DADA
Applied Materials should deliver beat and raise results, says DA Davidson
DA Davidson analyst Thomas Diffely expects Applied Materials to report beat and raise Q2 results on May 18. The analyst says that the "key near-term industry drivers," including the 3D NAND build-out, ramping foundries, and the recovery of DRAM capex, remain in place. He is also upbeat on the company's longer term outlook and keeps a Buy rating on the shares.
EGLT Egalet

01/10/17
GABE
01/10/17
DOWNGRADE
GABE
Hold
Egalet downgraded to Hold from Buy at Gabelli
05/12/17
GABE
05/12/17
UPGRADE
GABE
Buy
Egalet upgraded to Buy on valuation at Gabelli
Gabelli analyst Kevin Kedra upgraded Egalet to Buy from Hold with a 2018 PMV of $9.50 saying shares are oversold following Arymo approval. The analyst said Arymo is off to a slow start but said potential managed care wins and approval of abuse deterrence labeling for Oxaydo could prove to be near-term catalysts. Longer-term, Kedra said Egalet is well positioned to benefit from the shift away from older opiods without abuse deterrence features.
10/26/16
JANY
10/26/16
NO CHANGE
JANY
Neutral
Egalet's Arymo faces increased risk from Morphabond, says Janney Capital
Janney Capital analyst Ken Trbovich noted that privately held Inspirion Delivery Sciences entered into a collaboration agreement that gives Daiichi Sankyo rights to commercialize Morphabond, which means that product may be commercialized before Egalet's Arymo, which is "tied up in a delay of unknown duration" with the FDA. Morphabond being the first abuse-deterrent, extended-release morphine-based product to launch without a blackbox warning for co-ingestion with alcohol will make it more difficult for Egalet to gain traction with Arymo, said Trbovich, who keeps a Neutral rating on the shares.
01/10/17
STFL
01/10/17
NO CHANGE
STFL
Egalet Arymo outlook still positive, says Stifel
After the FDA approved Egalet's Arymo pain medicine but did not approve an oral or intranasal claim, Stifel analyst Annabel Samimy still thinks the drug has a large market opportunity and room for penetration. She keeps a $21 price target and a Buy rating on the shares.
NVDA Nvidia
$133.07

5.35 (4.19%)

05/18/17
BERN
05/18/17
INITIATION
Target $165
BERN
Outperform
Nvidia initiated with an Outperform at Bernstein
Bernstein initiated Nvidia with an Outperform and a $165 price target.
05/12/17
RBCM
05/12/17
NO CHANGE
RBCM
Nvidia price target raised to $150 from $138 at RBC Capital
After attending Nvidia's Analyst Day, RBC Capital analyst Mitch Steves raised his price target on Nvidia. The analyst thinks that the company's high margin data center revenue should grow by triple digit percentage levels and he estimates that its artificial intelligence revenue is increasing "more than 200%." He keeps an Outperform rating on the stock.
05/12/17
ADAM
05/12/17
NO CHANGE
Target $155
ADAM
Buy
Nvidia price target raised to $155 from $125 at Canaccord
Canaccord analyst Matthew Ramsay raised his price target on Nvidia to $155 from $125 following its strong Q1 results. The analyst noted that GPU computing continues to accelerate, particularly in the datacenter, adding that he believes datacenter sales approaching $4B+ are possible in the next 3 years. Ramsay reiterated his Buy rating on Nvidia shares.
05/15/17
GSCO
05/15/17
NO CHANGE
Target $165
GSCO
Conviction Buy
Nvidia price target raised to $165 from $130 at Goldman Sachs
Goldman Sachs analyst Toshiya Hari said hte market continues to under-appreciate Nvidia's Datacenter long-term growth opportunity. Hari was surprised by last week's launch of Volta and the associated improvement in performance and sees meaningful upside to Street estimates for FY18/19. The analyst remains positive on Nvidia's positioning in AI/ML inference market and 2020 TAM forecasts provided by the company and reiterates his Coviction Buy rating.
XBIT XBiotech
$8.82

-0.13 (-1.45%)

06/28/16
NBLE
06/28/16
NO CHANGE
Target $30
NBLE
Buy
XBiotech price target raised to $30 from $24 at Noble Financial
Noble Financial raised XBiotech's price target to $30 from $24 due to the C. difficile program initiation, Phase 1/2 programs in NSCLC psoriasis diabetes, a rich pipeline driven by True Human Antibody platform, increased probability of success for mCRC to 70% in Europe and 35% in the US. The firm has a Buy rating on XBiotech shares.
HALO Halozyme
$14.16

0.4 (2.91%)

01/05/17
PIPR
01/05/17
NO CHANGE
Target $20
PIPR
Overweight
Halozyme price target raised to $20 after pancreas cancer data at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target on Halozyme to $20 from $18, saying the company's "encouraging" Phase 2 data for its pancreas cancer combination treatment reduce the risk to the ongoing Phase 3 program for the combo. Duncan keeps an Overweight rating on Halozyme.
03/30/17
DBAB
03/30/17
NO CHANGE
Target $17
DBAB
Buy
Halozyme price target raised to $17 from $15 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme to $17 saying the positive, "unanimous and uncontroversial" FDA Advisory Committee meeting for Rituxan-SC highlights the "strong potential" for the broader Enhanze platform. The analyst reiterates a Buy rating on the shares.
04/17/17
BMOC
04/17/17
INITIATION
Target $14
BMOC
Market Perform
Halozyme initiated with a Market Perform at BMO Capital
BMO Capital initiated Halozyme with a Market Perform and a $714 price target.
01/06/17
SBSH
01/06/17
DOWNGRADE
Target $14
SBSH
Neutral
Halozyme downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Halozyme Therapeutics to Neutral saying the "mixed" Phase 2 pancreatic cancer data for PEGPH20 suggested the market opportunity is smaller than previously thought. The analyst believes the shares are now fairly valued. He keeps a $14 price target for the name.
GSBD Goldman Sachs BDC
$23.08

-0.25 (-1.07%)

03/02/17
RAJA
03/02/17
DOWNGRADE
RAJA
Market Perform
Goldman Sachs BDC downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Robert Dodd downgraded Goldman Sachs BDC to Market Perform due to valuation, lower fees and interest rates.
01/18/17
WELS
01/18/17
DOWNGRADE
WELS
Market Perform
Goldman Sachs BDC downgraded on valuation at Wells Fargo
As noted earlier, Wells Fargo downgraded Goldman Sachs BDC to Market Perform from Outperform. The firm downgraded the stock based on valuation. Target $21.50-$22.50.
03/01/17
FBCO
03/01/17
NO CHANGE
Target $24
FBCO
Neutral
Goldman Sachs BDC price target raised to $24 from $19.50 at Credit Suisse
Credit Suisse analyst Douglas Harter raised his price target for Goldman Sachs BDC to $24 from $19.50 as the company continues to "comfortably cover" the 45c/quarter dividend, leaving room for a dividend increase later in 2017. The analyst reiterates a Neutral rating on the shares.
01/18/17
WELS
01/18/17
DOWNGRADE
WELS
Market Perform
Goldman Sachs BDC downgraded to Market Perform from Outperform at Wells Fargo
RSPP RSP Permian
$40.69

0.2 (0.49%)

04/26/17
LEHM
04/26/17
INITIATION
Target $44
LEHM
Overweight
RSP Permian reinstated with an Overweight at Barclays
Barclays analyst Jeffrey Robertson reinstated coverage of RSP Permian with an Overweight rating and $44 price target.
03/23/17
UBSW
03/23/17
UPGRADE
Target $53
UBSW
Buy
RSP Permian upgraded to Buy from Neutral at UBS
UBS analyst Betty Jiang upgraded RSP Permian to Buy saying the company's exposure in the core of the Delaware Basin should drive production upside. The analyst raised her price target for the shares to $53 from $45.
04/12/17
STFL
04/12/17
INITIATION
Target $46
STFL
Buy
RSP Permian initiated with a Buy at Stifel
Stifel initiated RSP Permian with a Buy and a $46 price target saying it offers compelling growth and value, at a relatively in-line valuation, with a strong management team and an asset base that is generating top tier growth and improving productivity and depth.
04/10/17
GSCO
04/10/17
UPGRADE
Target $63
GSCO
Buy
RSP Permian upgraded to Buy from Neutral at Goldman
Goldman Sachs analyst John Nelson upgraded RSP Permian to Buy and raised his price target for the shares to $63 from $41. The company's acquisition of Silver Hill's core Delaware Basin assets should further expand its acreage quality advantage, Nelson tells investors in a research note. The analyst expects the stock to outperform over the next 12 months.

TODAY'S FREE FLY STORIES

LRLCY

L'Oreal

$42.24

-0.165 (-0.39%)

18:47
05/29/17
05/29
18:47
05/29/17
18:47
Periodicals
Renhe Pharmacy mulls joining auction for The Body Shop, Sky News says »

China's Renhe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$153.61

-0.26 (-0.17%)

, QCOM

Qualcomm

$57.52

-0.93 (-1.59%)

18:43
05/29/17
05/29
18:43
05/29/17
18:43
Periodicals
Apple hires former Qualcomm VP to head SoC efforts, AppleInsider says »

Apple (AAPL) has hired…

AAPL

Apple

$153.61

-0.26 (-0.17%)

QCOM

Qualcomm

$57.52

-0.93 (-1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

GS

Goldman Sachs

$223.53

1.06 (0.48%)

18:40
05/29/17
05/29
18:40
05/29/17
18:40
Periodicals
Goldman Sachs bought $2.8B in Venezuelan bonds, WSJ says »

Goldman Sachs purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 18

    Jul

  • 17

    Oct

ICAGY

IAG

$15.65

-0.305 (-1.91%)

18:36
05/29/17
05/29
18:36
05/29/17
18:36
Hot Stocks
British Airways suffers 'major' IT failure »

IAG's British…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.01

-0.47 (-0.61%)

18:20
05/29/17
05/29
18:20
05/29/17
18:20
Hot Stocks
Canadian National reaches tentative labor with train conductors, yard employees »

CN announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$107.24

0.33 (0.31%)

, AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

16:29
05/29/17
05/29
16:29
05/29/17
16:29
Hot Stocks
PPG says remains willing to engage with AkzoNobel »

PPG (PPG) issued the…

PPG

PPG

$107.24

0.33 (0.31%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$107.24

0.33 (0.31%)

, AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

16:27
05/29/17
05/29
16:27
05/29/17
16:27
Periodicals
Court rejects Elliott challenge against AkzoNobel, Bloomberg says »

The Dutch Commercial…

PPG

PPG

$107.24

0.33 (0.31%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$108.41

1.14 (1.06%)

, VIA

Viacom

16:21
05/29/17
05/29
16:21
05/29/17
16:21
Hot Stocks
Box Office Battle: 'Pirates' wins holiday weekend as 'Baywatch' stumbles »

Disney's (DIS)…

DIS

Disney

$108.41

1.14 (1.06%)

VIA

Viacom

VIAB

Viacom

$35.13

0.21 (0.60%)

FOX

21st Century Fox

$26.95

-0.28 (-1.03%)

FOXA

21st Century Fox

$27.03

-0.3 (-1.10%)

TWX

Time Warner

$99.07

0.1025 (0.10%)

CMCSA

Comcast

$40.91

0.57 (1.41%)

CMCSK

Comcast

LGF.A

Lionsgate

$27.76

2.21 (8.65%)

LGF.B

Lionsgate

$25.56

2.11 (9.00%)

SNE

Sony

$36.68

0.51 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

  • 12

    Jun

  • 15

    Jun

  • 15

    Jun

  • 27

    Jun

DGAS

Delta Natural Gas

15:56
05/29/17
05/29
15:56
05/29/17
15:56
Conference/Events
Delta Natural Gas to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBRC

FBR & Co.

$17.65

0.65 (3.82%)

15:51
05/29/17
05/29
15:51
05/29/17
15:51
Conference/Events
FBR & Co. to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

GM

General Motors

$33.07

0.47 (1.44%)

15:38
05/29/17
05/29
15:38
05/29/17
15:38
Hot Stocks
General Motors says ISS recommends vote against Greenlight proposal »

General Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABX

Barrick Gold

$16.38

0.39 (2.44%)

15:30
05/29/17
05/29
15:30
05/29/17
15:30
Hot Stocks
Barrick Gold reports start, resolution of work stoppage at Veladero mine »

Barrick Gold reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WBAI

500.com

$9.62

0.86 (9.82%)

15:27
05/29/17
05/29
15:27
05/29/17
15:27
Hot Stocks
500.com to acquire shares of MelcoLot Limited »

500.com announced a share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.21

0.07 (0.63%)

15:02
05/29/17
05/29
15:02
05/29/17
15:02
Hot Stocks
Rent-A-Center says partly disagrees with ISS recommendation on board vote »

Rent-A-Center issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

NAT

Nordic American Tankers

$5.97

-0.58 (-8.86%)

14:58
05/29/17
05/29
14:58
05/29/17
14:58
Earnings
Nordic American Tankers reports Q1 EPS (3c), may not compare to consensus (6c) »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.16

-0.03 (-0.58%)

, NFLX

Netflix

$162.43

-0.62 (-0.38%)

14:51
05/29/17
05/29
14:51
05/29/17
14:51
Hot Stocks
Israel's Partner Communications announces partnership with Netflix »

Partner Communications…

PTNR

Partner Communications

$5.16

-0.03 (-0.58%)

NFLX

Netflix

$162.43

-0.62 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 05

    Jun

APOP

Cellect Biotechnology

$9.24

-0.14 (-1.49%)

14:48
05/29/17
05/29
14:48
05/29/17
14:48
Earnings
Cellect Biotechnology reports Q1 EPS (3.7c), one estimate (22c) »

Reports Q1 R&D spend…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIC

Richmont Mines

$7.05

-0.15 (-2.08%)

14:43
05/29/17
05/29
14:43
05/29/17
14:43
Hot Stocks
Richmont Mines reports 'strong' results from Island Gold Mine assessment »

Richmont Mines announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
05/29/17
05/29
14:40
05/29/17
14:40
General news
Canada Current Account Preview »

Canada Current Account…

14:35
05/29/17
05/29
14:35
05/29/17
14:35
General news
Canada Industrial Product Price Index Preview »

Canada Industrial Product…

HTHT

China Lodging

$79.24

1.97 (2.55%)

14:33
05/29/17
05/29
14:33
05/29/17
14:33
Hot Stocks
China Lodging completes Crystal Orange transaction, says plans guidance revision »

China Lodging Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$74.90

-0.29 (-0.39%)

14:27
05/29/17
05/29
14:27
05/29/17
14:27
Hot Stocks
Arrow Electronics collaborates with Singapore's AIRmaker on startup acceleration »

Arrow Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

NDAQ

Nasdaq

$67.58

-0.61 (-0.89%)

14:25
05/29/17
05/29
14:25
05/29/17
14:25
Hot Stocks
Nasdaq selected to power Kazakhstan stock exchange »

Nasdaq and Astana…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 07

    Jun

  • 15

    Jun

ESLT

Elbit Systems

$121.00

-0.02 (-0.02%)

14:10
05/29/17
05/29
14:10
05/29/17
14:10
Hot Stocks
Elbit Systems says awarded $390M electronic intelligence contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.01

-0.47 (-0.61%)

14:08
05/29/17
05/29
14:08
05/29/17
14:08
Hot Stocks
Canadian National says train conductors, yard employees give strike notice »

CN said Saturday that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.